File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL

Conference Paper: Capecitabine but not 5-FU worsened hepatosplenomegaly and liver function when used with oxaliplatin and cetuximab as first-line treatment in K-ras wild-type metastatic colorectal cancer

TitleCapecitabine but not 5-FU worsened hepatosplenomegaly and liver function when used with oxaliplatin and cetuximab as first-line treatment in K-ras wild-type metastatic colorectal cancer
Authors
KeywordsMedical sciences
Oncology medical sciences
Radiology and nuclear medicine pharmacy and pharmacology biology
Cytology and histology
Issue Date2013
PublisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/
Citation
The 2013 Annual Meeting of the American Society of Clinical Oncology® (ASCO 2013), Chicago, IL., 31 May-4 June 2013. In Journal of Clinical Oncology, 2013, v. 31 n. 15 suppl., abstract no. e14530 How to Cite?
AbstractBACKGROUND: MRC COIN study showed that OXA and CAP (CAPOX) have greater toxicities compared with OXA and 5-FU (FOLFOX) when cetuximab (C225) was added for mCRC. Meanwhile, OXA was associated with splenomegaly and hepatic sinusoidal injury. We investigated if CAPOX+C225 worsened hepatosplenomegaly and liver function compared with FOLFOX+C225 in K-rasWT mCRC. METHODS: 97 patients with K-ras WT mCRC received either FOLFOX or CAPOX ...
DescriptionTheme: Building Bridges to Conquer Cancer
This abstract will not be presented at the 2013 ASCO Annual Meeting but has been published in conjunction with the meeting - http://meetinglibrary.asco.org/content/113435-132
Persistent Identifierhttp://hdl.handle.net/10722/194878
ISSN
2015 Impact Factor: 20.982
2015 SCImago Journal Rankings: 9.204

 

DC FieldValueLanguage
dc.contributor.authorLee, VHFen_US
dc.contributor.authorFang, WJen_US
dc.contributor.authorLam, KOen_US
dc.contributor.authorChoi, CWen_US
dc.contributor.authorNg, SCYen_US
dc.contributor.authorHo, PPYen_US
dc.contributor.authorHo, GCLen_US
dc.contributor.authorCheng, TKCen_US
dc.contributor.authorLiu, RKYen_US
dc.contributor.authorLeung, TWen_US
dc.contributor.authorKwong, DLWen_US
dc.contributor.authorZheng, Sen_US
dc.date.accessioned2014-02-17T02:15:02Z-
dc.date.available2014-02-17T02:15:02Z-
dc.date.issued2013en_US
dc.identifier.citationThe 2013 Annual Meeting of the American Society of Clinical Oncology® (ASCO 2013), Chicago, IL., 31 May-4 June 2013. In Journal of Clinical Oncology, 2013, v. 31 n. 15 suppl., abstract no. e14530en_US
dc.identifier.issn0732-183Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/194878-
dc.descriptionTheme: Building Bridges to Conquer Canceren_US
dc.descriptionThis abstract will not be presented at the 2013 ASCO Annual Meeting but has been published in conjunction with the meeting - http://meetinglibrary.asco.org/content/113435-132-
dc.description.abstractBACKGROUND: MRC COIN study showed that OXA and CAP (CAPOX) have greater toxicities compared with OXA and 5-FU (FOLFOX) when cetuximab (C225) was added for mCRC. Meanwhile, OXA was associated with splenomegaly and hepatic sinusoidal injury. We investigated if CAPOX+C225 worsened hepatosplenomegaly and liver function compared with FOLFOX+C225 in K-rasWT mCRC. METHODS: 97 patients with K-ras WT mCRC received either FOLFOX or CAPOX ...en_US
dc.languageengen_US
dc.publisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/en_US
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.subjectMedical sciencesen_US
dc.subjectOncology medical sciencesen_US
dc.subjectRadiology and nuclear medicine pharmacy and pharmacology biologyen_US
dc.subjectCytology and histologyen_US
dc.titleCapecitabine but not 5-FU worsened hepatosplenomegaly and liver function when used with oxaliplatin and cetuximab as first-line treatment in K-ras wild-type metastatic colorectal canceren_US
dc.typeConference_Paperen_US
dc.identifier.emailLee, VHF: vhflee@hku.hken_US
dc.identifier.emailLam, KO: lamkaon@hku.hken_US
dc.identifier.emailChoi, CW: hcchoi@hku.hken_US
dc.identifier.emailNg, SCY: ngchoryi@hku.hken_US
dc.identifier.emailLiu, RKY: ricoliu@hkucc.hku.hken_US
dc.identifier.emailLeung, TW: ltw920@hkucc.hku.hken_US
dc.identifier.emailKwong, DLW: dlwkwong@hku.hken_US
dc.identifier.authorityLee, VHF=rp00264en_US
dc.identifier.authorityLam, KO=rp01501en_US
dc.identifier.authorityKwong, DLW=rp00414en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros227709en_US
dc.identifier.volume31en_US
dc.identifier.issue15 suppl.en_US
dc.publisher.placeUnited Statesen_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats